CGM metrics predict risk for stage 3 type 1 diabetes better than patient characteristics

ORLANDO — Continuous glucose monitoring metrics can predict imminent stage 3 type 1 diabetes for people who are islet autoantibody positive, according to a speaker at the American Diabetes Association Scientific Sessions.
Researchers compared predictive models for stage 3 type 1 diabetes using data from five study groups. A predictive model using CGM metrics outperformed a model incorporating patient characteristics only. Peter Calhoun, PhD, a biostatistician at the Jaeb Center for Health Research, said the findings show how CGM can be used to predict risk for imminent stage 3 type 1

ORLANDO — Continuous glucose monitoring metrics can predict imminent stage 3 type 1 diabetes for people who are islet autoantibody positive, according to a speaker at the American Diabetes Association Scientific Sessions.
Researchers compared predictive models for stage 3 type 1 diabetes using data from five study groups. A predictive model using CGM metrics outperformed a model incorporating patient characteristics only. Peter Calhoun, PhD, a biostatistician at the Jaeb Center for Health Research, said the findings show how CGM can be used to predict risk for imminent stage 3 type 1